Clinical Trials Logo

Filter by:
NCT ID: NCT01777776 Completed - Clinical trials for Locally Advanced or Metastatic BRAF Mutant Melanoma

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.

NCT ID: NCT01777308 Completed - Clinical trials for Infections, Meningococcal

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Start date: May 3, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' MenACWY-TT vaccine administered at 6 years post-primary vaccination with either GSK Biologicals' Hib-MenC-TT vaccine (Menitorix™) or Hiberix™ and Meningitec™, in healthy subjects aged 12-18 months at primary vaccination and to evaluate the long-term antibody persistence at 2 years after MenACWY-TT booster vaccination. This is an extension study of the Hib-MenC-TT-016 study (NCT number: NCT00326118).

NCT ID: NCT01777269 Completed - Clinical trials for Prostatic Hyperplasia

Prospective Sexual Function Study for BPH Subjects

Start date: February 18, 2013
Phase: Phase 4
Study type: Interventional

This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo. PRIMARY OBJECTIVE: To assess the change in sexual function from baseline to 1 year in sexually active men with at least moderate BPH who are treated with DUODART, compared to men treated with placebo .

NCT ID: NCT01777152 Completed - Clinical trials for Non-Hodgkin Lymphoma

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

ECHELON-2
Start date: January 31, 2013
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

NCT ID: NCT01776840 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

NCT ID: NCT01776567 Recruiting - Clinical trials for Coronary Artery Disease

Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms

APPOSE
Start date: July 2012
Phase: Phase 4
Study type: Interventional

The purpose of the trial is to directly compare the Cobalt Chromium platform everolimus-eluting stent, Xience Prime™, with the Platinum Chromium platform everolimus-eluting stent, Promus Element™, in relation to stent scaffolding shape, position with the heart blood vessel and extent of tissue coverage (at 6 months) using optical coherence tomography. Hypotheses: 1. The alloy composition and strut design of a drug-eluting stent has a direct bearing on stent apposition measured using OCT. 2. Stent design and alloy composition have a direct influence on radial support and scaffold shrinkage.

NCT ID: NCT01776541 Completed - Clinical trials for Pandemic H5N1 Influenza

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.

NCT ID: NCT01776528 Completed - Diabetes Mellitus Clinical Trials

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Start date: January 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.

NCT ID: NCT01776424 Completed - Clinical trials for Prevention & Control

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

COMPASS
Start date: February 28, 2013
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are: - To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD); - To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.

NCT ID: NCT01775137 Completed - Clinical trials for Long-term Safety of TIP

Ext. Long-term Safety Study in CF Patients: Single Arm TIP

Start date: February 2013
Phase: Phase 4
Study type: Interventional

The purpose of this extension study is to collect additional 48 weeks of safety data from patients taking TIP who have completed the core study CTBM100C2401. The purpose of collecting second year safety data through this study is to obtain long-term (2 years) safety data of TIP.